GEN Exclusives

More »

GEN News Highlights

More »
Sep 2, 2009

Positive Phase III Results Bring Nitec Closer to FDA Submission of RA Therapy

  • Nitec Pharma’s single-pulse, delayed-release prednisone tablet, Lodotra™, succeeded in a second Phase III trial in patients with rheumatoid arthritis (RA). The company says that data from this study called CAPRA-2 and previous CAPRA-1 trials will form the basis of a regulatory submission to FDA.

    The CAPRA-2 trial included 350 RA patients who demonstrated inadequate responses to DMARD therapies. Participants received either Lodotra or placebo in addition to their existing medication. The primary efficacy endpoint was at least a 20% improvement in a number of disease-specific criteria defined as the ACR-20 response rate.

    Results showed that 49% of Lodotra-treated patients achieved an ACR-20 response compared with 29% of patients in the placebo group. Lodotra treatment also led to a 44% reduction in morning stiffness, more than double that in the placebo group.

    Lodotra was launched in its first European market, Germany, in April this year by Merck KGaA, which holds exclusive distribution rights to the drug in that country and Austria. Germany is leading the decentralized European approval process for Lodotra.

    During March Nitec granted Mundipharma distribution rights to Lodotra across the rest of Europe. Nitec has retained all commercialization rights in the rest of the world.


Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »